• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Two-Year Rezdiffra Cirrhosis Data

    Simply Wall St·12/07/2025 00:30:05
    Listen to the news
    • Earlier this month, Madrigal Pharmaceuticals reported positive two-year Phase 3 data for its Rezdiffra treatment in patients with compensated MASH cirrhosis, while also granting equity inducement awards to 24 new non-executive employees under its 2025 Inducement Plan.
    • The new data strengthened investor focus on Rezdiffra’s potential role in advanced liver disease just as executives continued preset stock sale programs and analysts reiterated confidence in the drug’s commercial opportunity.
    • We’ll now examine how the encouraging two-year Rezdiffra cirrhosis data could reshape Madrigal’s investment narrative and long-term growth assumptions.

    The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

    Madrigal Pharmaceuticals Investment Narrative Recap

    To own Madrigal today, you have to believe Rezdiffra can become a foundational treatment across MASH stages while the company manages high spending and competitive pressure. The new two year cirrhosis data supports the key near term catalyst around expanding Rezdiffra’s use in advanced liver disease, but it does not remove the central risk of relying so heavily on a single asset and future trial readouts.

    The recent presentation of positive two year MAESTRO NAFLD 1 F4c data is most relevant here, because it directly informs expectations for Rezdiffra in compensated cirrhosis, where outcomes and safety will shape any future label expansion and commercial reach.

    Yet investors should also weigh how Madrigal’s dependence on Rezdiffra leaves them exposed if longer term safety or efficacy data in cirrhosis were to...

    Read the full narrative on Madrigal Pharmaceuticals (it's free!)

    Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028. This requires 68.6% yearly revenue growth and about a $1.1 billion earnings increase from -$281.9 million today.

    Uncover how Madrigal Pharmaceuticals' forecasts yield a $563.80 fair value, in line with its current price.

    Exploring Other Perspectives

    MDGL Community Fair Values as at Dec 2025
    MDGL Community Fair Values as at Dec 2025

    Six Simply Wall St Community fair value estimates for Madrigal range from US$460 to almost US$2,935 per share, underscoring very different views on upside. When you set those side by side with the central risk of Madrigal’s heavy reliance on Rezdiffra, it becomes even more important to compare several perspectives before forming an opinion.

    Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth over 5x more than the current price!

    Build Your Own Madrigal Pharmaceuticals Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    No Opportunity In Madrigal Pharmaceuticals?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.